Table 1.

Baseline characteristics of 303 HIV-infected Opioid Dependent Patients Receiving Buprenorphine/naloxone

Characteristic
Age, mean (SD)	45.2 (8.1)
% Male	67.7
Race/Ethnicity
% White	22.7
% Black	51.5
% Hispanic	22.4
% Other	3.3
% High school education or greater	57.6
% Employed	25.7
% Heroin user*	61.3
% Heroin/other opioid user*	21.1
% Other opioids*	17.6
% Injection drug use at treatment entry	60.1
Years of opioid dependence, mean (SD)	17.21 (11.1)
% Recent alcohol use	49.2
% Recent cocaine use	66.0
% Recent methamphetamine use	6.0
CES-D score, mean (SD)	2.45 (0.73)
ASI Alcohol Score score, mean (SD)	8.56 (11.9)
ASI Drug Score score, mean (SD)	32.03 (12.9)
Years of HIV diagnosis, mean (SD)	12.2 (6.5)
% Antiretroviral treatment at treatment entry	59.9
CASE Adherence Index Score	11.1 (6.5)
Baseline CD4, mean (SD)	353 (261)
Baseline log HIV RNA, mean (SD)	3.47 (1.1)

^*256/303 reported heroin or prescription opioid use within 30 days of starting buprenorphine/naloxone.